Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma

Autor:	C. Carr, H. Xie, Anthony W. Tolcher, K. Berg, L.-L. Hwang, J. McCann, Frank V. Fossella, R. Fram
Rok vydání:	2005
Předmět:	Drug Cancer Research business.industry media_common.quotation_subject HuN901-DM1 medicine.disease Maytansinoid Small-cell carcinoma Immunoconjugate chemistry.chemical_compound Oncology chemistry Cancer research Cytotoxic T cell Medicine In patient Murine monoclonal antibody business media_common
Zdroj:	Journal of Clinical Oncology. 23:7159-7159
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2005.23.16_suppl.7159
Popis:	7159 Background: BB-10901 is an immunoconjugate created by conjugation of the cytotoxic maytansinoid drug DM1 to a humanized version of the murine monoclonal antibody N901. BB-10901 binds with high...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c9989d0ae56d518d470c5a619cab0cd9 https://doi.org/10.1200/jco.2005.23.16_suppl.7159 Zobrazit plný text záznamu